Strategies and challenges involved in the discovry of new chemical entities during early-stage tuberculosis drug discovery

Research output: Contribution to conferencePaper

Abstract

There is an increasing flow of new antituberculosis chemical entities entering the tuberculosis drug development pipeline. Although this is encouraging, the current number of compounds is too low to meet the demanding criteria required for registration, shorten treatment duration, treat drug-resistant infection, and address pediatric tuberculosis cases. More new chemical entities are needed urgently to supplement the pipeline and ensure that more drugs and regimens enter clinical practice. Most drug discovery projects under way exploit enzyme systems deemed essential in a specific Mycobacterium tuberculosis biosynthetic pathway or develop chemical scaffolds identified by phenotypic screening of compound libraries, specific pharmacophores or chemical clusters, and natural products. Because the development of a compound for treating tuberculosis is even longer than for treating other infection indications, the identification of selective, potent, and safe chemical entities early in the drug development process is essential to ensure that the pipeline is filled with new candidates that have the best chance to reach the clinic.
Original languageEnglish
Publication statusPublished - 2012
EventTuberculosis: Local and global - London, United Kingdom
Duration: 23 Mar 2012 → …

Conference

ConferenceTuberculosis: Local and global
CountryUnited Kingdom
CityLondon
Period23/03/12 → …

Fingerprint

Drug Discovery
Tuberculosis
Pharmaceutical Preparations
Biosynthetic Pathways
Infection
Biological Products
Mycobacterium tuberculosis
Libraries
Pediatrics
Enzymes

Keywords

  • tuberculosis
  • drug discovery

Cite this

@conference{59cd97f5919d41de972af0da4ae2fc54,
title = "Strategies and challenges involved in the discovry of new chemical entities during early-stage tuberculosis drug discovery",
abstract = "There is an increasing flow of new antituberculosis chemical entities entering the tuberculosis drug development pipeline. Although this is encouraging, the current number of compounds is too low to meet the demanding criteria required for registration, shorten treatment duration, treat drug-resistant infection, and address pediatric tuberculosis cases. More new chemical entities are needed urgently to supplement the pipeline and ensure that more drugs and regimens enter clinical practice. Most drug discovery projects under way exploit enzyme systems deemed essential in a specific Mycobacterium tuberculosis biosynthetic pathway or develop chemical scaffolds identified by phenotypic screening of compound libraries, specific pharmacophores or chemical clusters, and natural products. Because the development of a compound for treating tuberculosis is even longer than for treating other infection indications, the identification of selective, potent, and safe chemical entities early in the drug development process is essential to ensure that the pipeline is filled with new candidates that have the best chance to reach the clinic.",
keywords = "tuberculosis , drug discovery",
author = "Geoffrey Coxon",
year = "2012",
language = "English",
note = "Tuberculosis: Local and global ; Conference date: 23-03-2012",

}

Coxon, G 2012, 'Strategies and challenges involved in the discovry of new chemical entities during early-stage tuberculosis drug discovery' Paper presented at Tuberculosis: Local and global, London, United Kingdom, 23/03/12, .

Strategies and challenges involved in the discovry of new chemical entities during early-stage tuberculosis drug discovery. / Coxon, Geoffrey.

2012. Paper presented at Tuberculosis: Local and global, London, United Kingdom.

Research output: Contribution to conferencePaper

TY - CONF

T1 - Strategies and challenges involved in the discovry of new chemical entities during early-stage tuberculosis drug discovery

AU - Coxon, Geoffrey

PY - 2012

Y1 - 2012

N2 - There is an increasing flow of new antituberculosis chemical entities entering the tuberculosis drug development pipeline. Although this is encouraging, the current number of compounds is too low to meet the demanding criteria required for registration, shorten treatment duration, treat drug-resistant infection, and address pediatric tuberculosis cases. More new chemical entities are needed urgently to supplement the pipeline and ensure that more drugs and regimens enter clinical practice. Most drug discovery projects under way exploit enzyme systems deemed essential in a specific Mycobacterium tuberculosis biosynthetic pathway or develop chemical scaffolds identified by phenotypic screening of compound libraries, specific pharmacophores or chemical clusters, and natural products. Because the development of a compound for treating tuberculosis is even longer than for treating other infection indications, the identification of selective, potent, and safe chemical entities early in the drug development process is essential to ensure that the pipeline is filled with new candidates that have the best chance to reach the clinic.

AB - There is an increasing flow of new antituberculosis chemical entities entering the tuberculosis drug development pipeline. Although this is encouraging, the current number of compounds is too low to meet the demanding criteria required for registration, shorten treatment duration, treat drug-resistant infection, and address pediatric tuberculosis cases. More new chemical entities are needed urgently to supplement the pipeline and ensure that more drugs and regimens enter clinical practice. Most drug discovery projects under way exploit enzyme systems deemed essential in a specific Mycobacterium tuberculosis biosynthetic pathway or develop chemical scaffolds identified by phenotypic screening of compound libraries, specific pharmacophores or chemical clusters, and natural products. Because the development of a compound for treating tuberculosis is even longer than for treating other infection indications, the identification of selective, potent, and safe chemical entities early in the drug development process is essential to ensure that the pipeline is filled with new candidates that have the best chance to reach the clinic.

KW - tuberculosis

KW - drug discovery

UR - http://www.ucl.ac.uk/global-health/project-pages/symposia/tb-local-global

M3 - Paper

ER -